Romidepsin in the treatment of cutaneous T-cell lymphoma

By Salvia Jain, J. Zain. Journal of Blood Medicine, 2011

927 citations recorded by the source corpus.

The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are mycosis fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL are highly variable. Improving the management of this incurable disease with limited toxicity is an active area of research. Romidepsin is a novel, well-tolerated histone deacetylase inhibitor with promising activity against advanced stages of CTCL. In November 2009, it was approved by the US Food and Drug Administration for the treatment of CTCL in patients who have received at least one prior systemic therapy. This review focuses on the activity, pharmacology, and safety of romidepsin for the treatment of CTCL.

Subfields: Dermatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c9236bf00b0570729c6cbf9323f2c7b951a83436

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

  1. Gergely Ujhelyi
  2. Jared D. Smith
  3. Dilyan Donchev
  4. Rajeev Kumar Goel
  5. Toke S. Aidt
  6. M. A. Nelson

In Molecular Biology

  1. Gergely Ujhelyi
  2. Jared D. Smith
  3. Dilyan Donchev
  4. Rajeev Kumar Goel
  5. Toke S. Aidt
  6. M. A. Nelson

Citations in the corpus